ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021
Vulvovaginal candidiasis and current perspectives: new risk factors and laboratory diagnosis by using MALDI TOF for identifying species in primary infection and recurrence.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 48 citations in OpenAlex.
- Epidemiology, Diagnostics and Therapy of Vulvovaginal Fungal Infections.Pathogens (Basel, Switzerland) · 2026Review
- Epidemiology of vulvovaginal candidiasis in China: a six-year retrospective single-center study from a tertiary obstetrics and gynecology hospital in Shanghai.Microbiology spectrum · 2026Article
- Non-albicans Candida in Vulvovaginal Candidiasis: Antifungal Resistance and Expression of ERG11, CDR1, CDR2, and MDR1 Genes.MicrobiologyOpen · 2025Article
- Assessing the vulnerability of Candida colonization through social determinants of health among college students in Puebla, Mexico.Journal of health, population, and nutrition · 2025Article
- Prevalence of Candida and Other Yeasts in Vulvovaginal Infections during Pregnancy: A 10-Year Serbian Survey.Mycopathologia · 2025Article
- A Comprehensive Overview ofJournal of fungi (Basel, Switzerland) · 2025Review
- Genital cutaneous candidiasis versus chronic recurrent vulvovaginal candidiasis: distinct diseases, different populations.Clinical microbiology reviews · 2025Review
- Microbiological and clinical characteristics of vulvovaginitis in premenarcheal and postmenarcheal girls in a tertiary center in South Korea.Obstetrics & gynecology science · 2025Article
- Reproductive tract microbiome dysbiosis associated with gynecological diseases.Frontiers in cellular and infection microbiology · 2025Review
- Integrating Clinical and Microbiological Expertise to Improve Vaginal Candidiasis Management.Mycopathologia · 2024Article
- Diversity and Antifungal Susceptibilities of Yeasts from Mangroves in Hong Kong, China-A One Health Aspect.Journal of fungi (Basel, Switzerland) · 2024Article
- Insights and advances in recurrent vulvovaginal candidiasis.PLoS pathogens · 2023Article
- Draft genome sequence and probiotic functional property analysis of Lactobacillus gasseri LM1065 for food industry applications.Scientific reports · 2023Article
- Rare Yeasts in Latin America: Uncommon Yet Meaningful.Journal of fungi (Basel, Switzerland) · 2023Review
- Barriers and facilitators of adherence to treatment among women with vulvovaginal candidiasis: a qualitative study.European journal of medical research · 2022Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC), considered the second cause of genital infection among women, has pathogenic mechanisms still to be elucidated and unknown risk factors. Prevalence studies with laboratory diagnosis (at first diagnosis and recurrence) are uncommon, especially using MALDI TOF, used in this clinical, epidemiological, and laboratory study for evaluating candidiasis, and identifying unknown risk factors. To obtain clinical and epidemiological data, patients were questioned, and there was material collection. Samples collected were identified by using phenotypic and presumptive methods and confirmed by MALDI TOF. This study analyzed 278 patients, divided into symptomatic (n = 173) and asymptomatic (n = 105) groups. Regarding the main candidiasis symptoms (discharge, itching, and burning), only 50.3% of patients described these concomitant symptoms, showing a positive predictive value of 67.8%. Regarding the risk factors investigated, there was a statistical correlation between candidiasis and dairy products, gut transit, contraceptive use, respiratory allergy, and panty liners, describing new risk factors related to intestinal and vaginal dysbiosis. After Candida species analysis and confirmation, the primary prevalence was 80.9% (Candida albicans), 15.2% (non-albicans), 1% (Rhodotorula mucilaginosa), and 1.9% (unidentified species). In recurrence, the prevalence was 66.7% (C. albicans) and 33.3% (non-albicans). The presence of symptoms has low positive predictive value for the diagnosis of candidiasis, even when considering the classic triad of symptoms. Laboratory identification of yeast species is essential for correct treatment, preventing the resistance to antifungals and the high recurrence. In addition, dairy products and bowel habits, both related to intestinal and vaginal dysbiosis, may be associated with VVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.